Biomarker may guide chemo choices for pancreatic cancer patients

NCT ID NCT04472910

First seen Mar 19, 2026 · Last updated May 16, 2026 · Updated 11 times

Summary

This study looks at whether a biomarker called GATA6 can help predict how well chemotherapy works for people with pancreatic cancer that can be surgically removed. About 84 participants will receive chemotherapy before and after surgery, and researchers will measure their GATA6 levels to see if it relates to how long they stay cancer-free. The goal is to move toward personalized treatment strategies instead of a one-size-fits-all approach.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RESECTABLE PANCREATIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • BC Cancer Agency Vancouver

    Vancouver, British Columbia, Canada

  • Jewish General Hospital

    Montreal, Quebec, Canada

  • Kingston Health Sciences Centre

    Kingston, Ontario, Canada

  • London Health Sciences Centre

    London, Ontario, Canada

  • Ottawa Hospital

    Ottawa, Ontario, Canada

  • Princess Margaret Cancer Centre

    Toronto, Ontario, M5G 2N9, Canada

  • Sunnybrook Hospital/Odette Cancer Centre

    Toronto, Ontario, Canada

  • Unity Health (St. Joseph's and St. Michael's)

    Toronto, Ontario, Canada

Conditions

Explore the condition pages connected to this study.